With insights from the PEGASUS-TIMI 54 study, it was assessed whether patients with higher lipoprotein A treated with ticagrelor, a P2Y12 inhibitor, have a greater reduction in cardiovascular risk. In this touchCARDIO interview, we speak with Dr Siddharth Patel (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) to discuss the role of lipoprotein A in atherogenesis and the findings of his study presented at ESC 2022.Â
The abstract entitled ‘Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trial’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What is the role of anti-platelet therapy in chronic secondary prevention of atherothrombotic events in patients who have experienced a heart attack? (0:18)
- What is known about the role of lipoprotein A in atherogenesis? (1:24)
- What was the rationale for and design of the PEGASUS-TIMI 54 study? (2:18)
- What were the findings of the study? (3:06)
- On the basis of these findings, what are your recommendations for clinical practice? (4:02)
Disclosures: Siddharth Patel has received grant or research support from National Heart, Lung and Blood Institute (T32HL007604).
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Cardiovascular Risk here
